Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03077529
Other study ID # 163046
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date March 20, 2017
Est. completion date September 6, 2018

Study information

Verified date April 2018
Source Maastricht University Medical Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The population is aging worldwide, concomitant frailty is increased in older age groups. Frailty has a strong impact on outcomes of multi-morbidity and daily living, thereby negatively influencing quality of life and health care costs. Prevention or delay of onset of frailty associated with aging is needed. Dietary intake of galacto-oligosaccharides (GOS) may have beneficial effects on microbiota composition and health outcome parameters. As microbiota composition and function may be altered in elderly compared to younger adults, it will investigated whether the effects of GOS on selected parameters of microbiota and gut health differ between elderly versus younger adults. The primary objective of this study is to compare the effects of four weeks GOS supplementation on intestinal microbiota composition and activity in elderly versus younger adults. Further, this study has four secondary objectives. The study conforms to a randomized double-blind placebo-controlled cross-over design per age-group. Study populations are human volunteers (male and female), healthy young adults of 25-50 years and prefail older adults of 70-85 years old, BMI 20-30 kg/m2. One intervention period subjects will receive 7.2 grams of Vivinal® GOS Powder three times daily for four weeks. The other intervention period subjects will receive isocaloric placebo supplements (5.7 grams maltodextrin) three times daily for four weeks. At the start and end of each intervention period, several measurements will take place. There will be a washout period of four to five weeks between intervention periods. The main study parameter is the change in microbial composition and activity induced by GOS intervention, in younger adults and elderly.


Recruitment information / eligibility

Status Completed
Enrollment 44
Est. completion date September 6, 2018
Est. primary completion date September 6, 2018
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 25 Years to 85 Years
Eligibility Inclusion Criteria:

1. Based on medical history no gastrointestinal complaints can be defined.

2. Age 25 - 50 years and classified as 'robust' by the Fried frailty criteria, or age 70 - 85 years and classified as 'prefrail' by the Fried frailty criteria.

3. Body Mass Index (BMI) = 20 and < 30 kg/m2.

4. Weight-stable for at least 90 days prior to participation (no change in bodyweight, i.e. < 3kg).

5. Hemoglobin value of 8.2-11.0 mmol/L for men, 7.3-9.7 mmol/L for women.

6. C-reactive protein (CRP) value of <10 mg/L.

7. Creatinin value of 60-115 µmol/L for men, 50-100 µmol/L for women.

8. Alanine transaminase (ALAT) value of <45 U/L for men, 34 U/L for women.

9. Gamma-glutamyl transpeptidase (GGT) value of <55 U/L for men, <38 U/L for women.

10. Will be informed in case of any unexpected finding.

Exclusion Criteria:

1. History of severe cardiovascular, respiratory, urogenital, gastrointestinal/ hepatic, hematological/immunologic, HEENT (head, ears, eyes, nose, throat), dermatological/connective tissue, musculoskeletal, metabolic/nutritional, endocrine, neurological diseases, major surgery and/or laboratory assessments which might limit participation in or completion of the study protocol.

2. Self-admitted human immunodeficiency virus-positive state.

3. Disease with a life expectancy shorter than 5 years.

4. Abdominal surgery interfering with gastrointestinal function, upon judgment of the medical doctor, who will decide on in- or exclusion based on the surgery applied.

5. Use of antibiotics products within 90 days prior to the study.

6. Use of other medication will be reviewed by a medical doctor, who will decide on in- or exclusion based on the drug(s) used.

7. Use of laxatives within 14 days prior to the study.

8. Institutionalized (e.g. hospital or nursing home).

9. Pregnancy or lactation.

10. Plan to lose weight or follow a specific diet within the study period.

11. Alcohol intake >14 units/week.

12. Drug use.

13. Blood donation within 30 days prior to the study.

14. Administration of probiotic or prebiotic supplements, investigational drugs or participation in any scientific intervention study, which may interfere with this study (to be decided by the principle investigator), in the 14 days prior to the study.

15. History of side effects towards intake of prebiotic supplements.

16. Self-admitted lactose intolerance

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Galacto-oligosacchride
During this period subjects will receive 5.65 grams of Vivinal GOS supplements three times daily for four weeks
Maltodextrin
During this period subjects will receive 7.24 grams of maltodextrin supplements three times daily for four weeks

Locations

Country Name City State
Netherlands Maastricht University Medical Center Maastricht

Sponsors (2)

Lead Sponsor Collaborator
Maastricht University Medical Center Wageningen University

Country where clinical trial is conducted

Netherlands, 

Outcome

Type Measure Description Time frame Safety issue
Primary Microbial composition Microbiota composition and functional capacity as measured by HiSeq sequencing of fecal 16S rRNA genes. Change from baseline to four weeks supplementation, of each intervention period
Primary Microbial activity Microbial activity as measured by metabolites, such as organic acids analysis in feces and plasma. Change from baseline to four weeks supplementation, of each intervention period
See also
  Status Clinical Trial Phase
Not yet recruiting NCT04391777 - Determine the Effect of the Fourth Ventricle Compression Technique on Physiological Variables N/A
Completed NCT01561716 - An Evaluation of the Energy Expenditure From Wii Fit Games N/A
Completed NCT05876663 - Effect of Kinesio Taping on Pulmonary Function and Forward Shoulder Posture FSP of Young Adults N/A
Completed NCT05515926 - Physiological Responses to Osteopathic Manipulative Techniques in Healthy Young Adults N/A
Completed NCT03628976 - Noninvasive Vagus Nerve Stimulation (VNS) for Neuromotor Adaptations N/A
Completed NCT03094520 - Cognitive Embodiment Activation by tDCS N/A
Completed NCT02376270 - Pectin, Aging and Intestinal Barrier Function Phase 4
Completed NCT02110407 - Modulation of Visual-Spatial Learning in Healthy Young Adults by tDCS N/A
Not yet recruiting NCT05407259 - Investigating the Inverted-U Relationship Between Cognitive Performance and Plasma Epinephrine N/A
Completed NCT03452761 - Effects of Exogenous Ketones in Healthy Young Adults N/A
Completed NCT06043076 - iTBS Effect on M1 Plasticity, Blood Glucose, and Cardiovascular Response N/A
Completed NCT04207528 - Campus Life Study: Harnessing Generativity Among Young Adults N/A
Completed NCT02851017 - Exergaming Versus Gym-based Exercise for Postural Control, Flow and Technology Acceptance N/A
Completed NCT04302155 - Wii Fit as Balance Assessment and Training N/A
Completed NCT02794298 - tDCS Effects on GABA Concentration and Brain Functional Connectivity in Young Adults N/A